FullHope Biomedical Co.,Ltd.

NT$24.00As of Sun 8 Nov 2026, 12:00 UTC

TPEx:7773Healthcare

Country Taiwan

PE (Fwd) —

TSR 2Y CAGR (27.84%)

Div yield —

ROE (6.86%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (34.43%)

Mkt cap NT$957.9M

ROIC (8.71%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

NT$25

3.94%

(57.86%)

Price above Reference Value

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

43.60

RevenueNT$M

—

14.31

24.71

20.50

43.60

56.47

44.97%

—

112.63

Revenue growth%

—

72.70

(17.03)

112.63

29.51

72.70

—

75.80

Gross margin%

—

62.71

52.28

65.91

75.80

75.15

64.31

—

(109.67)

Operating margin%

—

(308.32)

(177.51)

(313.95)

(109.67)

(100.00)

(242.91)

—

(89.33)

Net margin%

—

(305.76)

(168.90)

(272.65)

(89.33)

(80.78)

(220.77)

—

P/E ratio (avg)x

—

EV/EBITx

—

(2.55)

FCF yield (avg)%

—

(3.85)

(1.50)

(2.76)

(2.68)

—

(56.12)

FCF margin%

—

(287.55)

(137.95)

(320.96)

(56.12)

(46.77)

(212.75)

—

0.628

FCF / Net incomex

—

0.940

0.817

1.177

0.628

—

0.879

—

(8.71)

ROIC%

—

(69.13)

(15.07)

(12.02)

(8.71)

(10.55)

(13.54)

—

(6.86)

Return on equity%

—

(60.88)

(12.64)

(9.53)

(6.86)

(8.64)

(11.08)

—

(6.82)

Return on assets%

—

(48.18)

(6.91)

(9.15)

(6.82)

(8.46)

(8.03)

—

(0.98)

EPSNT$

—

(1.78)

(1.46)

(1.43)

(0.98)

(1.14)

—

31.60

EPS growth%

—

18.04

2.21

31.60

(17.12)

18.04

—

13.80

Bookvalue per shNT$

—

2.92

20.58

14.92

13.80

12.66

67.73%

—

(0.61)

FCF per shareNT$

—

(1.67)

(1.19)

(1.68)

(0.61)

(0.66)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

39.91

Shares (diluted)M

—

24.58

28.61

39.19

39.91

◌39.91

17.53%

—

(1.84)

Buyback yield%

—

(16.40)

(36.97)

(1.84)

◌—

(16.40)

—

0.014

D/E ratiox

—

0.083

—

0.020

0.014

0.041

0.017

—

0.952

Enterprise valueNT$B

—

1.677

1.625

0.979

(3.08%)

—

LT debtNT$M

—

13.20

—

Peers (US$31.34M)

Cap (US$)

Genomics BioSci…

34.79M

—

SMOBiO Technology, Inc

19.68M

—

Han.biomedical Inc.

17.11M

—

Quratis Inc.

30.91M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(140.6)

(299.7)

Own earn%

—

Sh yield%

(1.84)

(16.40)

Owners

Insiders/Inst%

31.50

4.65

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

2/3

EPS growth years

3/3

Dividend streakyrs

Op margin range%

−314–−110

$1 testx

—

Incr. ROIC%

−1

FullHope Biomedical Co.,Ltd. engages in the research and development of immune system-related services. It develops FHCT001 and FHCT003, an immune cell therapies for cancer; and FHCT002, an auto-immune cell therapy, as well as diagnostic tools.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$43.60M

44.97%

1.00×

Cost of revenue

NT$10.55M

25.52%

0.65×

Operating expenses

NT$80.86M

15.05%

0.50×

Asset mix

Trend

Other

97.69%

Cash and investments

2.31%

Reinvestment returns

No breakdown available